Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment

Relevance . Angiogenesis inhibitors in the treatment of age-related macular degeneration (AMD) do not eliminate the oxidative stress associated with this pathology. Purpose : evaluation of complex therapy for neovascular AMD (nAMD) combining the nutraceutical Resvera Forte® (VISUS LAB LLC) with intravitreal administration of aflibercept. Patients and methods . The study involved 36 patients (36 eyes) with nAMD, aged 72.0 ± 3.8 years. Two groups were formed, comparable by gender and age. In the main group (20 patients), in addition to aflibercept therapy, an oral course of the multivitamin complex Resvera Forte® (712 mg) was prescribed. In the comparison group (16 patients, 16 eyes), aflibercept therapy was administered. The observation period was 1.5 years. Results . After three “loading” intravitreal injections of aflibercept, all 36 patients showed a decrease in macular neovascularization activity, the interval was increased by 2 weeks. By 12 months, no patient in the main group had AMD activity, the central retinal thickness (CRT) decreased to 251.5±9.1 μm, and the best-corrected visual acuity (BCVA) increased to 0.8 ± 0.06. The average number of intravitreal injections per year in the main group was 7 ± 1. In the comparison group, six patients showed resumption of AMD activity, which required an increase in the number of injections to 9–10 per year. CRT was 293.0 ± 20.3 μm versus 251.5 ± 9.1 μm in the main group (p < 0.08). The BCVA in the comparison group was 0.8 ± 0.06 versus 0.6 ± 0.09 in the main group (p < 0.05). Conclusion . Supplementation of anti-VEGF therapy for nAMD with the oral nutraceutical Resvera Forte® contributed to an objective improvement in the morphofunctional results of its treatment.